Summary of Study ST003031

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001884. The data can be accessed directly via it's Project DOI: 10.21228/M8672X This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003031
Study Title	Early time-restricted eating improves markers of cardiometabolic health but has no impact on nutrient absorption in healthy adults
Study Type	Randomized Controlled Trial
Study Summary	Metabolomic analysis performed on 88 human plasma samples collected from 16 participants that received 2 treatments with 3 time points each. Samples were analyzed by UPLC-MS using a Waters Acquity UPLC and detected on a 4000 QTrap by multiple reaction monitoring (MRM) with negative mode electrospray ionization.
Institute	California Polytechnic State University, San Luis Obispo
Last Name	La Frano
First Name	Michael
Address	Cal Poly State University 1 Grand Avenue San Luis Obispo, CA 93407
Email	mlafrano@calpoly.edu
Phone	(805) 756-6233
Submit Date	2023-12-15
Num Groups	2
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2024-01-23
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003154
Treatment Summary:	This study was approved by the Florida State University Institutional Review Board and registered on clinicaltrials.gov (NCT04877262). Healthy, adults who were normal-weight (BMI:18.5-24.9 kg/m2) or overweight (BMI: 25-29.9 kg/m2) and 23-42 y, were recruited from the greater Tallahassee, Florida area between December 2021 and May 2022 and provided informed consent prior to participating. Potential participants were excluded if they had any disease or condition known to interfere with metabolism or normal gastrointestinal function (diabetes, cardiovascular disease, kidney disease, prior bariatric surgery, suspected or known fistulas, gastrointestinal obstruction, gastrointestinal disease, colonoscopy within 3 months of the study, alcoholism, substance abuse disorders); irregular menstrual cycle in the past 6 months; weight fluctuations greater that 5% during the previous 6 months; antibiotic use within 3 months of participation; allergies or intolerances to foods included in the controlled diet; habitual use of laxatives, stool softeners, or anti-diarrheal medications (≥ 1x/week); whole-gut transit time >72 h; or were pregnant or lactating. Participants followed an early time-restricted eating (eTRE) schedule (i.e., all meals consumed in a 6-h window between 0800 and 1400) and a control eating schedule (i.e., all meals consumed in a 12-h window between 0800 and 2000) for 9-d each in randomized order. On day 6 of each study period, participants arrived in the morning to the laboratory for a mixed-meal tolerance test (MMTT). Participants spent 6 hours in the laboratory to measure fasting (0h) and postprandial (2h and 4h) plasma metabolite concentrations in response to the MMTT. Whole blood was collected in EDTA vacutainer tubes (BD Vacutainer, Franklin Lakes, New Jersey, USA) and centrifuged at 3000 RPM for 15 minutes at 4°C before aliquots were frozen at -80°C until analysis.

Treatment ID:

TR003154

Treatment Summary:

This study was approved by the Florida State University Institutional Review Board and registered on clinicaltrials.gov (NCT04877262). Healthy, adults who were normal-weight (BMI:18.5-24.9 kg/m2) or overweight (BMI: 25-29.9 kg/m2) and 23-42 y, were recruited from the greater Tallahassee, Florida area between December 2021 and May 2022 and provided informed consent prior to participating. Potential participants were excluded if they had any disease or condition known to interfere with metabolism or normal gastrointestinal function (diabetes, cardiovascular disease, kidney disease, prior bariatric surgery, suspected or known fistulas, gastrointestinal obstruction, gastrointestinal disease, colonoscopy within 3 months of the study, alcoholism, substance abuse disorders); irregular menstrual cycle in the past 6 months; weight fluctuations greater that 5% during the previous 6 months; antibiotic use within 3 months of participation; allergies or intolerances to foods included in the controlled diet; habitual use of laxatives, stool softeners, or anti-diarrheal medications (≥ 1x/week); whole-gut transit time >72 h; or were pregnant or lactating. Participants followed an early time-restricted eating (eTRE) schedule (i.e., all meals consumed in a 6-h window between 0800 and 1400) and a control eating schedule (i.e., all meals consumed in a 12-h window between 0800 and 2000) for 9-d each in randomized order. On day 6 of each study period, participants arrived in the morning to the laboratory for a mixed-meal tolerance test (MMTT). Participants spent 6 hours in the laboratory to measure fasting (0h) and postprandial (2h and 4h) plasma metabolite concentrations in response to the MMTT. Whole blood was collected in EDTA vacutainer tubes (BD Vacutainer, Franklin Lakes, New Jersey, USA) and centrifuged at 3000 RPM for 15 minutes at 4°C before aliquots were frozen at -80°C until analysis.